Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 11,411

Document Document Title
WO/2020/184336A1
Provided is a liquid metal complex having oxygen-absorbing ability and containing: a cobalt acacene complex or a derivative thereof; and an ionic liquid in which an ionic ligand having an amine structure and a counter ion thereof are pai...  
WO/2020/176686A1
The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP5...  
WO/2020/175495A1
Provided is a method for producing a salt by reacting M+X- with YH so as to generate XH and M+Y-, and then removing the generated XH so as to obtain M+Y-. M+X- is a salt of a cation represented by M+ and an anion represented by X-. M+Y- ...  
WO/2020/168290A1
Provided herein are methods for treating a disease, such as cancer, the methods including administering one or more N-aryl benezenesulfonamides or analogs thereof to a subject in need thereof.  
WO/2020/157771A1
The present invention relates to preparation of pyrazoles. This invention further relates to a continuous flow micro-total process system for preparation of celecoxib, a COX-2 selective non-steroidal anti-inflammatory drug, and analogs t...  
WO/2020/157126A1
The present invention relates to a class of novel compounds of general formula (I), their use as medicaments and pharmaceutical compositions comprising them. Specifically, the compounds of the invention are useful as voltage-gated potass...  
WO/2020/160140A1
Disclosed in certain embodiments is a method of treating a pulmonary disease comprising administering a therapeutically effective amount of a Matrix Metalloproteinase (MMP) Inhibitor to a patient in need thereof wherein the pulmonary dis...  
WO/2020/154499A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/154321A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula (AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/151799A1
The present invention relates to improved (simplified/easier, more robust and more reproducible) methods for identification of carbohydrates compositions, e.g. out of complex carbohydrate mixtures, as well as the determination of carbohy...  
WO/2020/151804A1
Sulfonated 2(7)-aminoacridone and 1-aminopyrene dyes and their use as fluorescent tags, in particular for carbohydrate analysis The invention relates to fluorescent dyes with multiple negatively charged groups in their ionized form which...  
WO/2020/154214A1
Provided herein is a method of administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is being administered an organic anion transporter-1 (OAT1) inhibitor and/or ...  
WO/2020/148619A1
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...  
WO/2020/148760A1
The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.  
WO/2020/146274A1
The present technology is directed to fluorinated alkylsulfonamide electrolyte salts with high solubility, conductivity, and electrochemical stability as well as batteries incorporating fluorinated alkylsulfonamide salts. In any aspect a...  
WO/2020/142809A1
A method and an angioplasty balloon catheter used in a method of preventing or minimizing incidence of neointimal hyperplasia (NIH) in a blood vessel of an animal following angioplasty treatment. The method comprising locating the angiop...  
WO/2020/102901A8
Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium...  
WO/2020/127960A1
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.  
WO/2020/124262A1
The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a cell proliferative disorder such as a cancer using a compound of formula (I) ...  
WO/2020/127675A1
Described are colour developers of formula (I) Ar1-SO2-NH-C6H4-SO2-C6H4-NH-CO-NH-Ar2 (I), a heat-sensitive recording material, comprising a base substrate and also a heat-sensitive, colour-forming layer comprising at least one colour for...  
WO/2020/115419A1
The invention relates to a process for producing a compound having the following formula (III): R2-(SO2)-NLi-(SO2)-F (III) wherein said process comprises: - a step b) which comprises: - a step b1) of fluorinating a compound having the fo...  
WO/2020/112934A1
Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate t...  
WO/2020/112935A1
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chos...  
WO/2020/112672A1
The present invention is based in part on the identification of biomarkers, including NQOl, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof.  
WO/2020/109720A1
The invention relates to a process for producing lithium bis(fluorosulfonyl)imide salt. The present invention discloses a process for producing lithium bis(fluorosulfonyl)imide salt involving the following steps: a) a step of producing b...  
WO/2020/104634A1
This invention relates to compounds of general formula: wherein R0A and R0B are independently selected from hydrogen and pharmaceutically acceptable cations; and RA and RB are identical and selected from amide, carbamate, sulphonamide, a...  
WO/2020/102901A1
Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium...  
WO/2020/102576A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/102574A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/091054A1
The invention provides a novel production method for an isoquinoline-6-sulfonamide derivative that is useful as a medicinal drug, and also provides an intermediate for use in the method. The invention is the 1,4-diazocane compound repres...  
WO/2020/084854A1
The fluorinated imide salt compound of the present invention is a compound represented by general formula (1). In general formula (1), m is 1 or 2, n is an integer of 1-4, α is 1 or 2, and Xα+ represents an α-valent metal ion, a prima...  
WO/2020/086728A1
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/081999A1
The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating ...  
WO/2020/074403A1
The present invention relates to small molecule compounds capable of modulating appetite in a vertebrate animal, particularly in a mammal. The invention further relates to the use of the compounds of the invention in methods of treatment...  
WO/2020/072605A1
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...  
WO/2020/063854A1
Disclosed are a class of quinoline-based derivatives and the use thereof in the preparation of a medicament for treating diseases related to VAP-1, and specifically disclosed are a compound represented by formula (II) and a pharmaceutica...  
WO/2020/067398A1
The purpose of the present invention is to provide: a novel compound that inhibits cell invasion of filovirus; a medicinal composition that comprises the compound; an anti-filovirus agent or an inhibitor for cell invasion of filovirus; a...  
WO/2020/061367A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2020/051099A1
The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as...  
WO/2020/050215A1
Provided for the purpose of efficient oxide production is a method for producing an oxide by oxidation of a starting compound in the presence of oxygen, characterized in that the starting compound is oxidized in the presence of manganese...  
WO/2020/041301A1
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the ...  
WO/2020/035466A1
The present invention relates to compounds of formula (I): wherein A, B, X, Y, R1, R4 and R7 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical ...  
WO/2020/031836A1
A polymerizable ionic liquid according to the present invention includes a compound comprising: an anion that has a predetermined structure and that includes a perfluoroalkyl group and a polymerizable functional group in the molecule the...  
WO/2020/027150A1
A compound represented by general formula (I) (wherein each symbol is as defined in the description) or a salt thereof has a potent neural protecting and/or repairing effect and, therefore, is usable as a therapeutic agent for neurologic...  
WO/2020/016427A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2020/018944A1
In one aspect, the present disclosure provides methods of inhibiting STAT3 in a cell comprising contacting the cell with a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosur...  
WO/2020/010140A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/006177A1
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2019/241851A1
The present invention relates to compounds that have the ability to inhibit lysine biosynthesis via the diaminopimelate pathway in certain organisms. As a result of this activity these compounds can be used in applications where inhibiti...  
WO/2019/229357A1
The present invention relates to a process for preparing a compound of formula (III):: R2-(SO2)-N Li-(SO2)-F, said process comprising: - a step b) comprising: a step b1) of fluorination of a compound of following formula (I): R1-(SO2)-NH...  

Matches 1 - 50 out of 11,411